Dyslipidemia is closely related to cardiovascular disease. In the past 10 years, a series of milestone clinical trials of blood lipid intervention have been completed at home and abroad. These findings strongly confirm that lowering cholesterol levels significantly reduces the incidence of cardiovascular events in patients with cardiovascular diseases and high-risk groups, so lowering cholesterol to achieve the target is regarded as the core strategy for the prevention and treatment of cardiovascular diseases. Conclusive evidence shows that statins play an important role in the primary and secondary prevention of atherosclerotic cardiovascular diseases, and the rational use of such drugs can significantly reduce the morbidity and mortality of cardiovascular diseases. In clinical practice, many patients' cholesterol levels still can't reach the target value after receiving statin therapy, and some patients can't tolerate statin therapy, which has become an important obstacle to improve the compliance rate of blood lipid. In addition, the safety of high-dose statins in order to achieve cholesterol standards is also attracting increasing attention. The cholesterol-lowering effect of statins was only increased by about 6% after doubling the dose, but the risk of related adverse events (especially elevated liver enzymes, myopathy, and effects on glucose metabolism) was associated with the dose of statins, and the risk of adverse events was significantly increased. The advent of selective cholesterol absorption inhibitors provides a new means for lowering cholesterol more effectively. In order to promote and standardize the rational use of such drugs, academic institutions such as the Cardiovascular Physicians Branch of Chinese Medical Doctors Association, the Cardiovascular and Cerebrovascular Disease Professional Committee of Chinese Gerontological Society and the Evidence-based Medicine Professional Committee of Chinese Medical Doctors Association organized domestic experts to formulate and update the "Chinese Expert Consensus on Clinical Application of Cholesterol Absorption Inhibitors" in 2010 and 2011, respectively. After the release of the consensus, it attracted widespread attention in China and played a positive role in enhancing clinicians' understanding of cholesterol absorption inhibitors. A number of recently published clinical and basic studies have further clarified the mechanism of action and efficacy of such drugs alone or in combination with statins. This revision of this consensus document aims to provide more comprehensive information for the rational use of selective cholesterol absorption inhibitors.
